Feng Wang

Online Now: Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer dlvr.it/TR3PY0

@Annals_Oncology @YanceyChen_lol Final analysis of Jupiter-06 study showed the EGIC model is effective in predicting the long term survival. Potential combination strategies are provided.

🆕article in press: Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma @FengWan25720657 @YanceyChen_lol doi.org/10.1016/j.anno…

Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer dlvr.it/TQLTXT

We updated the long term survival data of Neosummit-01 trial. Always happy to meet friends. #ASCOGI26 #gastriccancer

#Garsorasib, alone or with #Cetuximab, shows strong efficacy, manageable safety, and a favorable response in heavily pretreated #KRASG12C-mutated metastatic #ColorectalCancer, supporting improved precision therapy outcomes. @FengWan25720657 #STTT: doi.org/10.1038/s41392…

Combo IO works better than single drug in the neoadjuvant setting in MSIH colorectal cancer. @Cancer_Cell

During the days I was in Lanzhou, Gansu, I walked along Yellow River everyday and was amazed by its magnificent view.

“The striking cover image showcases the dramatic meeting of the Tao River and the Yellow River in Gansu Province, China, where two distinct currents join to form a powerful, unified flow. This visual spectacle mirrors the findings of the Neoshot 1b study by Wang et al.,

Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors aacrjournals.org/cancerdiscover…

Phase II trial shows #KRASG12CInhibitor #Garsorasib, alone or with #cetuximab, delivers promising efficacy and manageable safety in heavily pretreated KRAS G12C–mutated #ColorectalCancer patients. @FengWan25720657 #STTT #OpenAccess: doi.org/10.1038/s41392…

Our preview of two very interesting papers. One from Dr Bardelli's lab, the other from Dr Diaz's group. @BardelliLab @ldiaz1971 @Cancer_Cell

It's always great to meet old friends and make new friends in ASCO.

Now at #ASCO24: In the phase 3 FRUTIGA trial, the multi anti-VEGFR inhibitor #fruquintinib + chemotherapy significantly extended progression-free survival, but not overall survival, as 2L therapy in patients with advanced #GastricCancer or #GEJCancer doi.org/10.1038/s41591…

Having fun at ASCO and meeting old friends. #ASCO24

Thanks to Cell for inviting us to write this commentary. Challenges and opportunities in oncology drug development and clinical research in China: Cell cell.com/cell/fulltext/… @CellCellPress

@YiHsinLiang1 Thank you, Yi-Hsin.

Great work! A novel pathway with amazing efficacy!

In a phase 2 trial comparing anti-PD-1 + anti-VEGF + HDAC inhibitor vs. anti-PD-1 + HDAC inhibitor in patients with MSS/pMMR #ColorectalCancer, the triplet combo leads to better 18 week progression-free survival. #ColorectalCancerAwarenessMonth nature.com/articles/s4159…

The Capability-01 trial was just published. The combination of HADCi, anti-PD-1 and anti-VEGF achieved an ORR of 44% with a mPFS 7.3 mos in MSS mCRC patients. Thanks to the study team, all patients and family. #colorectalcancer #Immunology #Cancer @NatureMedicine

Excited to share my recent work published in Nature Communications with the title "Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer." dlvr.it/T2z83z #MachineLearning #CancerGenomics 📚🔬